BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26855006)

  • 1. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
    Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
    Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.
    Kapanen M; Collan J; Saarilahti K; Heikkonen J; Kairemo K; Tenhunen M
    Radiother Oncol; 2009 Oct; 93(1):109-14. PubMed ID: 19435641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy.
    Murdoch-Kinch CA; Kim HM; Vineberg KA; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):373-82. PubMed ID: 18337023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.
    Lee SW; Kang KW; Wu HG
    Head Neck; 2016 Apr; 38 Suppl 1():E1746-55. PubMed ID: 26875880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of organ-at-risk sparing and plan robustness for spot-scanning proton therapy and volumetric modulated arc photon therapy in head-and-neck cancer.
    Barten DL; Tol JP; Dahele M; Slotman BJ; Verbakel WF
    Med Phys; 2015 Nov; 42(11):6589-98. PubMed ID: 26520750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment techniques for reduction in the submandibular gland dose: A retrospective study.
    Hoyne C; Dreosti M; Shakeshaft J; Baxi S
    J Med Radiat Sci; 2017 Jun; 64(2):125-130. PubMed ID: 28240447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy.
    Doornaert P; Verbakel WF; Rietveld DH; Slotman BJ; Senan S
    Radiat Oncol; 2011 Jun; 6():74. PubMed ID: 21679401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head and neck cancer: sites of locoregional relapse and survival.
    Collan J; Kapanen M; Mäkitie A; Nyman H; Joensuu H; Tenhunen M; Saarilahti K
    Acta Oncol; 2012 Jul; 51(6):735-42. PubMed ID: 22150115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.
    Scrimger RA; Seikaly H; Vos LJ; Harris J; O'Connell D; Ghosh S; Debenham B; Jha N
    Head Neck; 2018 Nov; 40(11):2353-2361. PubMed ID: 30175876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy: is xerostomia still prevalent?
    Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
    Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.